West Pharmaceutical Reports Strong Q2 Results, Details Cyber Incident Impact, and Boosts Share Buybacks
WST sits 60% above its 52-week low of $221.5 on elevated volume (2.1× avg).
Summary
West Pharmaceutical Services reported strong Q2 2026 financial results, demonstrating resilience after a May cybersecurity incident, while significantly increasing share repurchases and completing a strategic asset sale.
Key Events · Earnings and Guidance · WST
-
Strong Q2 Financial Performance
Net sales increased by 13.8% to $872.3 million, net income rose 16.8% to $154.0 million, and diluted EPS grew 18.1% to $2.15 ($2.37 adjusted), exceeding prior year figures.
-
Cybersecurity Incident Impact Detailed
The May 2026 cyber incident resulted in a $7 million negative impact on West Vantage segment revenue growth and $7.5 million in nonrecurring professional fees (SG&A) year-to-date, but the company is fully recovered.
-
Increased Share Repurchase Activity
The company repurchased $454.3 million of common stock (1.76 million shares) year-to-date under a new $1.0 billion program, significantly higher than $134.0 million in the prior year period.
-
SmartDose System Sale Completed
The sale of the SmartDose 3.5mL On-Body Delivery System to AbbVie was completed on July 1, 2026, generating approximately $136 million in cash proceeds and an expected pre-tax gain of $55-$60 million in Q3 2026.
Analysis · WST · Industrial Applications And Services
West Pharmaceutical Services delivered robust second-quarter results, with significant growth in net sales, net income, and diluted EPS, confirming earlier news reports. The company provided detailed financial impacts of the May 2026 cybersecurity incident, including a $7 million revenue reduction in the West Vantage segment and $7.5 million in related SG&A costs year-to-date, but confirmed full operational recovery. A substantial increase in share repurchases under a new $1.0 billion program signals strong capital allocation and management confidence. The completion of the SmartDose system sale to AbbVie, with an expected $55-$60 million pre-tax gain in Q3, further strengthens the balance sheet and streamlines operations.
At the time of this filing, WST was trading at $354.08 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $25.1B. The 52-week trading range was $221.50 to $386.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.